Kymera stock is a new Outperform at RBC (KYMR:NASDAQ)


Business on Wall Street in Manhattan

Pgiam/iStock via Getty Images

RBC Capital Markets launched its coverage of Kymera Therapeutics (NASDAQ:KYMR) with an Outperform rating on Tuesday, citing the potential of its lead drug KT-621, targeted at inflammatory conditions such as atopic dermatitis, commonly known as eczema.

RBC analyst Brian Abrahams



Source link

This useful free app lets you install Windows 11 on unsupported PCs cleanly

Mariah the Scientist Seen W/ Yung Miami, Drops 2026 Tour Dates

Leave a Reply

Your email address will not be published. Required fields are marked *